PMGC Holdings Inc.'s wholly-owned subsidiary, Northstrive Biosciences Inc., announced on March 27, 2025, a significant amendment to its existing License Agreement with MOA Life Plus Co., Ltd. This amendment expands Northstrive Biosciences’ license rights for EL-32 and EL-22 to include all uses in animal health, including feed additives.
The company believes this expanded scope will position Northstrive Biosciences to potentially capture new revenue streams from high-growth markets. It also aims to lower its barrier to entry within the animal health pharmaceutical sector.
This strategic move enhances Northstrive Biosciences’ licensing portfolio and reinforces its mission to deliver groundbreaking health solutions with high commercial potential. EL-22 leverages an engineered probiotic approach to address muscle preservation in weight loss treatments.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.